

Karen M Kuntz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/639157/publications.pdf>

Version: 2024-02-01

47
papers

4,702
citations

236612

25
h-index

264894

42
g-index

47
all docs

47
docs citations

47
times ranked

7496
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093.	3.8	2,149
2	Modeling Good Research Practices—Overview. Medical Decision Making, 2012, 32, 667-677.	1.2	389
3	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies. JAMA - Journal of the American Medical Association, 2016, 315, 2595.	3.8	388
4	State-Transition Modeling. Medical Decision Making, 2012, 32, 690-700.	1.2	231
5	Colorectal Cancer Screening. JAMA - Journal of the American Medical Association, 2021, 325, 1998.	3.8	145
6	Cost-Effectiveness of Computed Tomographic Colonography Screening for Colorectal Cancer in the Medicare Population. Journal of the National Cancer Institute, 2010, 102, 1238-1252.	3.0	125
7	Societal and Family Lifetime Cost of Dementia: Implications for Policy. Journal of the American Geriatrics Society, 2017, 65, 2169-2175.	1.3	113
8	The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials. American Journal of Medicine, 2014, 127, 1208-1232.	0.6	100
9	A Systematic Comparison of Microsimulation Models of Colorectal Cancer. Medical Decision Making, 2011, 31, 530-539.	1.2	96
10	Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. Journal of the National Cancer Institute, 2014, 106, dju160-dju160.	3.0	88
11	Secular Trends in Colon and Rectal Cancer Relative Survival. Journal of the National Cancer Institute, 2013, 105, 1806-1813.	3.0	76
12	Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population. Annals of Internal Medicine, 2010, 153, 368.	2.0	73
13	The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Seminars in Arthritis and Rheumatism, 2017, 46, 594-600.	1.6	67
14	Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777.	1.2	58
15	Validation of Models Used to Inform Colorectal Cancer Screening Guidelines. Medical Decision Making, 2016, 36, 604-614.	1.2	52
16	Clarifying Differences in Natural History between Models of Screening. Medical Decision Making, 2011, 31, 540-549.	1.2	45
17	A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. European Urology Oncology, 2019, 2, 649-655.	2.6	45
18	Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. Medical Decision Making, 2015, 35, 584-595.	1.2	43

#	ARTICLE	IF	CITATIONS
19	Linear Regression Metamodeling as a Tool to Summarize and Present Simulation Model Results. <i>Medical Decision Making</i> , 2013, 33, 880-890.	1.2	40
20	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. <i>PLoS ONE</i> , 2019, 14, e0220234.	1.1	39
21	Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. <i>Journal of Urology</i> , 2018, 200, 1215-1220.	0.2	36
22	Effects of cognition, function, and behavioral and psychological symptoms on out-of-pocket medical and nursing home expenditures and time spent caregiving for persons with dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 801-809.	0.4	34
23	Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. <i>European Urology</i> , 2019, 75, 910-917.	0.9	34
24	Cost-Effectiveness of Integrating a Clinical Decision Rule and Staged Imaging Protocol for Diagnosis of Appendicitis. <i>Value in Health</i> , 2016, 19, 28-35.	0.1	32
25	Cost-effectiveness Evaluation of Laparoscopic Versus Robotic Minimally Invasive Colectomy. <i>Annals of Surgery</i> , 2020, 272, 334-341.	2.1	29
26	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. <i>Gastroenterology</i> , 2018, 154, 105-116.e20.	0.6	26
27	Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 3846-3852.	0.7	22
28	Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1510-1518.	1.4	18
29	Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. <i>Value in Health</i> , 2014, 17, 310-319.	0.1	16
30	Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. <i>Health Services Research</i> , 2015, 50, 768-789.	1.0	16
31	Derivation of Background Mortality by Smoking and Obesity in Cancer Simulation Models. <i>Medical Decision Making</i> , 2013, 33, 176-197.	1.2	13
32	Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 729-740.	1.2	9
33	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1073-1085.	1.7	9
34	A Cost-Effectiveness Evaluation of Surgical Approaches to Proctectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1512-1523.	0.9	9
35	Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics - Open</i> , 2018, 2, 309-323.	0.9	8
36	Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. <i>Medical Decision Making</i> , 2020, 40, 1034-1040.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of spinal manipulation, exercise, and self-management for spinal pain using an individual participant data meta-analysis approach: a study protocol. <i>Chiropractic & Manual Therapies</i> , 2018, 26, 46.	0.6	5
38	Yield and Cost-effectiveness of Computed Tomography Colonography Versus Colonoscopy for Post Colorectal Cancer Surveillance. <i>MDM Policy and Practice</i> , 2018, 3, 238146831881051.	0.5	4
39	Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. <i>Pharmacoeconomics</i> , 2020, 38, 285-296.	1.7	4
40	Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation. <i>Value in Health</i> , 2020, 23, 1332-1339.	0.1	4
41	The effectiveness and value of novel treatments for cystic fibrosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 276-280.	0.5	4
42	Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer. <i>Value in Health</i> , 2022, 25, 36-46.	0.1	1
43	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv093-djv093.	3.0	0
44	Authors'™ response. <i>Journal of the American Dental Association</i> , 2016, 147, 231.	0.7	0
45	Cost-effectiveness of surveillance with CT colonography after resection of colorectal cancer. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000450.	1.1	0
46	Return to work after deceased donor kidney transplant under the kidney allocation system. <i>Clinical Transplantation</i> , 2021, 35, e14444.	0.8	0
47	A restricted look at CRC screening: not considering annual stool testing as an option. <i>American Journal of Managed Care</i> , 2016, 22, e270-4.	0.8	0